Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 2/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16597484 | 0.96 | GABRG2 (0.37) | GABRG2GABRB3GABRA5GABRA1GABRA2 | |
| SCHEMBL16610290 | 0.83 | GABRG2 (0.39) | GABRG2GABRB3GABRA5GABRA1GABRA2 | |
| SCHEMBL16597485 | 0.82 | GABRG2 (0.33) | GABRG2GABRB3GABRA5GABRA1GABRA2 | |
| SCHEMBL16597546 | 0.78 | NR1H2 (0.35) | GABRG2GABRB3GABRA5GABRA1GABRA2 | |
| SCHEMBL18012185 | 0.76 | GABRG2 (0.41) | GABRG2GABRB3GABRA5GABRA1GABRA2 | |
| SCHEMBL16597877 | 0.74 | GABRG2 (0.36) | GABRG2GABRB3GABRA5GABRA1GABRA2 | |
| SCHEMBL16610350 | 0.74 | GPR119 (0.46) | GABRG2GABRB3GABRA5GABRA1GABRA2 | |
| SCHEMBL23010089 | 0.72 | GABRG2 (0.38) | GABRG2GABRB3GABRA5GABRA1GABRA2 | |
| SCHEMBL16268180 | 0.72 | GABRG2 (0.38) | GABRG2GABRB3GABRA5GABRA1GABRA2 | |
| SCHEMBL16597821 | 0.71 | GABRG2 (0.42) | GABRG2GABRB3GABRA5GABRA1GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160228586-A1 | Compounds and Their Use for Preparation of Tau Imaging Agents and Tau Imaging Formulations | LILLY CO ELI (US) | 2016-08-11 | — | — | US | claimed |
| EP-3049414-A1 | COMPOUNDS AND THEIR USE FOR PREPARATION OF TAU IMAGING AGENTS AND TAU IMAGING FORMULATIONS | Eli Lilly and Company (US) | 2016-08-03 | — | — | EP | claimed |
| WO-2015047902-A1 | COMPOUNDS AND THEIR USE FOR PREPARATION OF TAU IMAGING AGENTS AND TAU IMAGING FORMULATIONS | ELI LILLY AND COMPANY (US) | 2015-04-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228586-A1 | Compounds and Their Use for Preparation of Tau Imaging Agents and Tau Imaging Formulations | MAPT, PSEN1, PSEN2 | GABRG2 2161/4885GABRB3 1780/4885GABRA5 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.